NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE Drug Patent Profile

When do Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expire, and when can generic versions of Norepinephrine Bitartrate In 0.9% Sodium Chloride launch?

Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug marketed by Inforlife and Long Grove Pharms and is included in two NDAs. There are eleven patents protecting this drug.

This drug has forty-nine patent family members in forty countries.

The generic ingredient in NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 0.9% Sodium Chloride

A generic version of NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE was approved as norepinephrine bitartrate by MEITHEAL on March 3^rd, 2003.

Summary for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

International Patents:	49
US Patents:	11
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is protected by eleven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes			Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes			Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes			Y
Inforlife	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	215700-001	Sep 15, 2022		RX	Yes	Yes			Y

International Patents for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

See the table below for patents covering NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	247501	תהליך להכנת תמיסה יציבה וניתנת להזרקה המכילה ריכוז נמוך של נוראדרנלין (Process for producing a stable low concentration, injectable solution of noradrenaline)
El Salvador	2016005265	PROCESO PARA PRODUCIR UNA SOLUCIÓN INYECTABLE DE NORADRENALINA DE BAJA CONCENTRACIÓN, ESTABLE
World Intellectual Property Organization (WIPO)	2015128418
Philippines	12016501703	PROCESS FOR PRODUCING A STABLE LOW CONCENTRATION, INJECTABLE SOLUTION OF NORADRENALINE

Norepinephrine Bitartrate in 0.9% Sodium Chloride: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Norepinephrine Bitartrate in 0.9% Sodium Chloride solutions is a critical vasopressor utilized predominantly in managing septic shock and hypotensive crises. The drug operates as a potent alpha-adrenergic agonist, constricting blood vessels to raise blood pressure effectively. This analysis offers a comprehensive review of the current and projected market landscape, investment opportunities, competitive environment, regulatory considerations, and financial trajectory, emphasizing the forecast horizon from 2023 to 2030.

Market Overview

Parameter	Details
Global Market Value (2022)	USD 1.2 billion
CAGR (2023–2030)	5.2%
Key Markets	United States, Europe, Asia-Pacific
Major Manufacturers	Pfizer, Japanese Pharma (Teva, Daiichi Sankyo), Mylan, Sandoz, and Hospira

Norepinephrine remains the first-line vasopressor in critical care settings, with hospital necessity driving steady demand. Demand is primarily driven by the increasing incidence of septic shock, aging populations, and expanding critical care units globally.

Market Dynamics

1. Drivers of Growth

• High Clinical Adoption: The American Heart Association and Surviving Sepsis Campaign recommend norepinephrine as the vasopressor of choice, reinforcing demand.
• Rising Septic Shock Incidence: According to WHO, sepsis affects over 30 million annually, with nearly 6 million deaths [1].
• Expansion of ICU Infrastructure: Emerging markets investing heavily in healthcare facilities increase drug utilization.
• Regulatory Favorability: The drug's long-established generic manufacturing pathway reduces barriers to market entry for generic manufacturers, fostering intense competition and price stability.

2. Challenges and Risks

• Pricing and Reimbursement Policies: Increasing governmental and insurance pressure to control healthcare costs can impact pricing strategies.
• Supply Chain Risks: Scarcity of raw materials or geopolitical tensions could impact manufacturing continuity.
• Regulatory Hurdles: Stringent approvals for biosimilars or new formulations may delay market expansion.
• Emerging Alternatives: Development of non-vasopressor therapies for shock management could threaten growth.

3. Competitive Landscape and Market Shares

Manufacturer	Estimated Market Share	Key Products	Notes
Pfizer	35%	Brand: Noradrenaline	Leading supplier in North America and Europe
Teva	20%	Generic versions	Focused on emerging markets
Sandoz	15%	Generic formulations	Expanding into critical care segments
Mylan (now part of Viatris)	10%	Broad generics	Focus on cost-effective solutions
Others	20%	Various generics	Regional players and emerging manufacturers

4. Regulatory and Patent Landscape

• Market Exclusivity: Many key brands licensed until 2025–2030, post which generics flood the market.
• Regulatory Pathways: Compliant manufacturing standards (USP, EP, JP standards) are mandatory.
• Biosimilars: No biosimilar versions currently; future entry expected post-patent expiry.

Financial Trajectory

1. Revenue Projections (2023–2030)

Year	Estimated Market Revenue (USD billion)	Growth Rate	Notes
2023	1.25	0% (Baseline)	Steady state post-COVID normalization
2024	1.33	6.4%	Driven by ICU and sepsis management
2025	1.40	5.3%	Approaching generic entry
2026	1.50	7.1%	Increased generic competition
2027	1.60	6.7%	Market normalization post-patent expiry
2028	1.70	6.3%	Growth stabilizes
2029	1.80	5.9%	Mature market plateau
2030	1.89	5.0%	Slight deceleration in growth

2. Cost Structure Breakdown

Cost Element	Percentage of Revenue	Explanation
Raw materials	25–30%	Epinephrine, sodium chloride, stabilizers
Manufacturing expenses	15–20%	Purity testing, aseptic processing
Regulatory compliance	5%	Inspections, documentation, post-market surveillance
Distribution and logistics	10–12%	Cold chain, global shipping
Marketing and sales	8–10%	For branded products in specific regions
Profit margins	15–20%	Varies with brand status and regional policies

3. Investment Opportunities

• Generics Expansion: Post-patent expiry, generic manufacturers can leverage low-cost production.
• Supply Chain Enhancements: Developing robust sourcing and contingency plans to mitigate raw material risks.
• Regulatory Navigation: Streamlining registration processes for biosimilar versions.
• Market Diversification: Targeting emerging economies for volume growth.
• Innovation: Exploring new formulations, stability improvements, or alternative delivery methods.

Comparison With Alternative Vasopressors

Drug Class	Examples	Advantages	Disadvantages
Norepinephrine	Noradrenaline	First-line for septic shock	Limited in bradyarrhythmia cases
Epinephrine	Adrenaline	Supports cardiac output	Higher risk of arrhythmias
Dopamine	Dopamine	Dose-dependent effects	Less preferred due to side effects
Vasopressin	Vasopressin	Can be adjunct therapy	Costlier, slower onset

Regulatory and Policy Landscape

• FDA Approval: Monographs and approval pathways via ANDA (Abbreviated New Drug Application).
• EMA: Centralized authorization for Europe.
• WHO Essential Medicines List: Norepinephrine included, ensuring global procurement.

Recent Trends and Innovations

• Stability Improvements: New formulations with extended shelf life.
• Delivery Devices: Development of infusion pumps and prefilled syringes enhancing safety and convenience.
• Biosimilar Entry: Anticipated post-patent expiry, poised to disrupt pricing dynamics.

---

Key Takeaways

• The overall global demand for norepinephrine bitartrate solutions in 0.9% sodium chloride is projected to grow at approximately 5.2% annually through 2030.
• Market growth is driven by increasing sepsis and critical care cases and infrastructure expansion, especially in emerging economies.
• Competition is intensifying with the expiration of patents, primarily favoring generic manufacturers, which will exert downward pressure on prices.
• High profitability margins exist for established brands; however, new entrants can offer competitive pricing with scalable manufacturing.
• Supply chain resilience and regulatory compliance are critical success factors.
• Alternative therapies and emerging formulations may influence future market share and growth trajectories.

---

FAQs

Q1: What are the primary drivers influencing the demand for norepinephrine in critical care?
A: The primary drivers include the rising incidence of septic shock, an aging population with increased comorbidities, expanding ICU capacity, and current clinical guidelines endorsing norepinephrine as the first-choice vasopressor.

Q2: How does patent expiry impact the competitive landscape?
A: Patent expiry enables generic manufacturers to enter the market, increasing competition, reducing prices, and potentially decreasing profit margins for branded products over time.

Q3: What are the main regulatory considerations for new entrants?
A: They include compliance with pharmacopeial standards, submission of abbreviated new drug applications (ANDAs), adherence to manufacturing cGMP standards, and navigating regional approval processes.

Q4: Which economies present the most significant growth opportunities?
A: Emerging markets in Asia-Pacific, Latin America, and the Middle East are poised for rapid growth due to expanding healthcare infrastructure and increasing critical care needs.

Q5: What are long-term risks to the financial trajectory of norepinephrine solutions?
A: Risks include regulatory hurdles, supply chain disruptions, competition from biosimilars, and technological advancements offering alternative shock management strategies.

---

References

1. World Health Organization. Sepsis Factsheet. 2022.
2. Surviving Sepsis Campaign. International Guidelines for Management of Sepsis and Septic Shock. 2021.
3. U.S. Food and Drug Administration. ANDA Pathways and Regulations. 2022.
4. MarketWatch. Global Vasopressor Market Report. 2022.
5. Centers for Disease Control and Prevention. Critical Care and Sepsis Data. 2023.

---

This analysis provides a strategic framework to inform stakeholders interested in the pharmaceutical market for norepinephrine bitartrate in 0.9% sodium chloride solutions, emphasizing critical factors influencing investment, market viability, and future trends.